Short report: Beneficial effects of benznidazole during an infectious-based situation of systemic inflammatory response: Cecal ligation and puncture

American Journal of Tropical Medicine and Hygiene

Volumn 79, Issue 5, 2008, Pages 793-796

  Manarin, Romina ^a,b   Bottasso, Emanuel ^a   Bottasso, Oscar ^a   Serra, Esteban ^b   Revelli, Silvia ^a  

^a FACULTAD DE CIENCIAS MÉDICAS   (Argentina)

^b UNIVERSIDAD NACIONAL DE ROSARIO   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

BENZNIDAZOLE; NITRIC OXIDE; TUMOR NECROSIS FACTOR ALPHA; ANTITRYPANOSOMAL AGENT; NITROIMIDAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BACTEREMIA; BACTERIAL GROWTH; CECAL LIGATION AND PUNCTURE; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; ENDOTOXEMIA; IMMUNOMODULATION; MALE; MOUSE; NONHUMAN; SEPSIS; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; ANIMAL; BLOOD; C57BL MOUSE; CHAGAS DISEASE; ENZYME LINKED IMMUNOSORBENT ASSAY; INFLAMMATION;

BACTERIA (MICROORGANISMS); MURINAE; MUS; RATTUS; TRYPANOSOMA CRUZI;

ANIMALS; BACTEREMIA; CHAGAS DISEASE; ENZYME-LINKED IMMUNOSORBENT ASSAY; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; NITROIMIDAZOLES; TRYPANOCIDAL AGENTS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 55849118825     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2008.79.793     Document Type: Article

References (13)

1. Revelli S, Le Page C, Piaggio E, Wietzerbin J, Bottasso O, 1999. Benznidazole, a drug employed in the treatment of Chagas' disease, down-regulates the synthesis of nitrite and cytokines by murine stimulated macrophages. Clin Exp Immunol 118: 271-277.
2. Piaggio E, Sanceau J, Revelli S, Bottasso O, Wietzerbin J, Serra E, 2001. Trypanocidal drug benznidazole impairs lipopolysaccharide induction of macrophage nitric oxide synthase gene transcription through inhibition of NF-kappa B activation. J Immunol 167: 3422-3426.
3. Piaggio E, Roggero E, Pitashny M, Wietzerbin J, Bottasso O, Revelli S, 2001. Treatment with benznidazole and its immunomodulating effects on Trypanosoma cruzi-infected rats. Parasitol Res 87: 539-547.
4. Pascutti MF, Pitashny M, Nocito A, Guermonprez P, Amigorena S, Wietzerbin J, Serra E, Bottasso O, Revelli S, 2004. Benznidazole, a drug used in Chagas' disease, ameliorates LPS-induced inflammatory response in mice. Life Sci 76: 685-697.
5. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ, 1992. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 101: 1644-1655.
6. Vassalli P, 1992. The pathophysiology of tumor necrosis factors. Annu Rev Immuno 110: 411-452.
7. Wichterman KA, Baue AE, Chaudry IH, 1980. Sepsis and septic shock a review of laboratory models and a proposal. J Surg Res 29: 189-201.
8. Deitch EA, 1998. Animal models of sepsis and shock: a review and lessons learned. Shock 9: 1-11.
9. Chung CS, Watkins L, Funches A, Lomas-Neira J, Cioffi WG, Ayala A, 2006. Deficiency of γδ T lymphocytes contributes to mortality and immunosuppression in sepsis. Am J Physiol Regul Integr Comp Physiol 291: R1338-R1343.
10. Gallos G, Jones DR, Nasr SH, Emala CW, Lee HT, 2004. Local anesthetics reduce mortality and Project against renal and hepatic dysfunction in murine septic peritonitis. Anesthesiology 101: 902-911.
11. Baker CC, Chaudry JH, Gaines HO, 1983. Evaluation of factors affecting mortality rate alter sepsis in a murine cecal ligation and puncture model. Surgery 94: 331-335.
12. Casey LC, Balk RA, Bon RC, 1993. Plasma cytokine and endotoxin levels correlate with survival in patients with sepsis syndrome. Ann Intern Med 119: 771-778.
13. Rodriguez Coura J, De Castro SL, 2002. A critical review on Chagas disease chemotherapy. Mem Inst Oswaldo Cruz 97: 3-24.